Inovio Pharmaceuticals Shares Touch 52-Week Low After $30M Offering

Dow Jones12-14

By Josh Beckerman

Shares of Inovio Pharmaceuticals fell to a 52-week low after the company reported the pricing of a $30 million offering.

The stock tumbled 40% to $2.27 in Friday trading, after falling to as low as $2.14 per share. For the year, the shares are down 63%.

Inovio said it sold 10 million shares and 10 million warrants at a combined public offering price of $3 per share and warrant. It disclosed plans for the sale on Thursday.

The company intends to use proceeds for purposes including development of its clinical pipeline, and preparing for the potential commercial launch of lead drug candidate INO-3107, if it's approved.

INO-3107, a potential treatment for recurrent respiratory papillomatosis, received Breakthrough Therapy designation from the Food and Drug Administration in September 2023.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

December 13, 2024 13:11 ET (18:11 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491306197?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-14 02:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491306197","market":"sh","top_or_hot":-1,"title":"Inovio Pharmaceuticals Shares Touch 52-Week Low After $30M Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Josh Beckerman \n</p>\n<p>\n  Shares of Inovio Pharmaceuticals fell to a 52-week low after the company reported the pricing of a $30 million offering. \n</p>\n<p>\n  The stock tumbled 40% to $2.27 in Friday trading, after falling to as low as $2.14 per share. For the year, the shares are down 63%. \n</p>\n<p>\n  Inovio said it sold 10 million shares and 10 million warrants at a combined public offering price of $3 per share and warrant. It disclosed plans for the sale on Thursday. \n</p>\n<p>\n  The company intends to use proceeds for purposes including development of its clinical pipeline, and preparing for the potential commercial launch of lead drug candidate INO-3107, if it's approved. \n</p>\n<p>\n   INO-3107, a potential treatment for recurrent respiratory papillomatosis, received Breakthrough Therapy designation from the Food and Drug Administration in September 2023. \n</p>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 13, 2024 13:11 ET (18:11 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inovio Pharmaceuticals Shares Touch 52-Week Low After $30M Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInovio Pharmaceuticals Shares Touch 52-Week Low After $30M Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-14 02:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Josh Beckerman \n\n\n  Shares of Inovio Pharmaceuticals fell to a 52-week low after the company reported the pricing of a $30 million offering. \n\n\n  The stock tumbled 40% to $2.27 in Friday trading, ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2491306197","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491306197","pubTimestamp":1734113460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Inovio Pharmaceuticals fell to a 52-week low after the company reported the pricing of a $30 million offering.The stock tumbled 40% to $2.27 in Friday trading, after falling to as low as $2.14 per share. For the year, the shares are down 63%.Inovio said it sold 10 million shares and 10 million warrants at a combined public offering price of $3 per share and warrant. It disclosed plans for the sale on Thursday.The company intends to use proceeds for purposes including development of its clinical pipeline, and preparing for the potential commercial launch of lead drug candidate INO-3107, if it's approved.INO-3107, a potential treatment for recurrent respiratory papillomatosis, received Breakthrough Therapy designation from the Food and Drug Administration in September 2023.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4568":"美国抗疫概念","BK4583":"猴痘概念","INO":"伊诺维奥制药"},"translate_title":"Inovio Pharmaceuticals发行3000万美元后股价触及52周低点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INO":1},"content_text":"By Josh Beckerman \n\n\n  Shares of Inovio Pharmaceuticals fell to a 52-week low after the company reported the pricing of a $30 million offering. \n\n\n  The stock tumbled 40% to $2.27 in Friday trading, after falling to as low as $2.14 per share. For the year, the shares are down 63%. \n\n\n  Inovio said it sold 10 million shares and 10 million warrants at a combined public offering price of $3 per share and warrant. It disclosed plans for the sale on Thursday. \n\n\n  The company intends to use proceeds for purposes including development of its clinical pipeline, and preparing for the potential commercial launch of lead drug candidate INO-3107, if it's approved. \n\n\n   INO-3107, a potential treatment for recurrent respiratory papillomatosis, received Breakthrough Therapy designation from the Food and Drug Administration in September 2023. \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 13, 2024 13:11 ET (18:11 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491306197"}